Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPINE 1: BAY 3283142 in Chronic Kidney Disease
NCT06522997Phase 2Completed
- Sponsor
- Bayer
- Start
- Aug 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of BAY3283142 in chronic kidney disease (CKD), sponsored by Bayer. Started Aug 2024; status: completed.
02
Drugs
BAY3283142
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06522997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06522997.